NCT05061758View on ClinicalTrials.gov

A Trial of LY3056480 in Patients With SNLH

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

September 30, 2022

Primary Completion Date

September 30, 2024

Study Completion Date

March 31, 2025

Conditions
Sensorineural Hearing Loss
Interventions
DRUG

LY3056480

LY3056480 is an inhibitor of gamma-secretase

Trial Locations (3)

10010

New York Eye and Ear Infirmary ICAHN school of Medicine Mount Sinai, New York

23507

Eastern Virginia Medical School, Norfolk

60611

Northwestern University Feinberg School of Medicine, Chicago

Sponsors
All Listed Sponsors
lead

Audion Therapeutics BV

INDUSTRY